Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 434Carcinoma, Non-Small-Cell Lung 360Neoplasms 339Prostatic Neoplasms 276Colorectal Neoplasms 264Multiple Myeloma 206Lung Neoplasms 195Neoplasm Metastasis 179Leukemia, Myeloid, Acute 160Ovarian Neoplasms 155Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 138Melanoma 126Recurrence 104Head and Neck Neoplasms 99Glioblastoma 99Carcinoma, Renal Cell 98Endometrial Neoplasms 96Carcinoma, Hepatocellular 93Lymphoma, Non-Hodgkin 92Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Lymphoma 91Triple Negative Breast Neoplasms 90Stomach Neoplasms 88Uterine Cervical Neoplasms 85Brain Neoplasms 85Lymphoma, Large B-Cell, Diffuse 80Urinary Bladder Neoplasms 77Glioma 74Leukemia, Lymphocytic, Chronic, B-Cell 73

Interventions

elacestrant 1RAD1901 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Endometrial Stromal × 30 days × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡